Growth Metrics

Eli Lilly (LLY) Payables (2016 - 2026)

Eli Lilly filings provide 18 years of Payables readings, the most recent being $5.0 billion for Q1 2026.

  • On a quarterly basis, Payables rose 46.11% to $5.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.0 billion, a 46.11% increase, with the full-year FY2025 number at $5.4 billion, up 17.57% from a year prior.
  • Payables hit $5.0 billion in Q1 2026 for Eli Lilly, down from $5.4 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.4 billion in Q2 2025 to a low of $1.4 billion in Q1 2022.
  • Median Payables over the past 5 years was $3.4 billion (2025), compared with a mean of $3.4 billion.
  • Biggest five-year swings in Payables: decreased 12.58% in 2022 and later surged 47.66% in 2025.
  • Eli Lilly's Payables stood at $2.9 billion in 2022, then grew by 27.82% to $3.8 billion in 2023, then rose by 21.43% to $4.6 billion in 2024, then rose by 17.57% to $5.4 billion in 2025, then fell by 6.51% to $5.0 billion in 2026.
  • The last three reported values for Payables were $5.0 billion (Q1 2026), $5.4 billion (Q4 2025), and $4.3 billion (Q3 2025) per Business Quant data.